Related Experiment Video

Updated: Apr 12, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.5K

Structural Differences between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors

Melissa A Lowder1, Amy E Doerner1, Alanna Schepartz1

  • 1Departments of †Chemistry, ‡Molecular Biophysics and Biochemistry, and §Molecular, Cellular, and Developmental Biology, Yale University, 225 Prospect Street, New Haven, Connecticut 06511, United States.

Journal of the American Chemical Society
|May 15, 2015
PubMed

Insights

Drug-resistant EGFR mutations in lung cancer have distinct structures outside the kinase domain. New TKIs restore normal structure, suggesting kinase-independent oncogenic roles and new therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Epidermal Growth Factor Receptor (EGFR) mutations drive non-small-cell lung cancer (NSCLC).
  • The double mutant (L858R/T790M) EGFR (DM EGFR) confers resistance to approved kinase inhibitors.
  • Targeting DM EGFR remains a significant challenge in NSCLC treatment.

Purpose of the Study:

  • To investigate structural differences between wild-type (WT) EGFR and DM EGFR.
  • To elucidate the mechanism by which third-generation EGFR TKIs target DM EGFR.
  • To explore potential kinase-independent oncogenic activities of DM EGFR.

Main Methods:

  • Bipartite tetracysteine display was employed to compare EGFR structures.
  • Structural analysis focused on the cytoplasmic juxtamembrane (JM) segment.
  • Allosteric effects of third-generation TKIs on JM structure were assessed.

Main Results:

  • DM EGFR exhibits structural variations compared to WT EGFR outside the kinase domain.
  • A key structural difference resides in the cytoplasmic juxtamembrane (JM) segment.
  • Third-generation DM EGFR-selective TKIs induce allosteric changes in JM structure, restoring a WT-like conformation.

Conclusions:

  • EGFR structural differences extend beyond the kinase domain, involving the JM segment.
  • DM EGFR may possess oncogenic activities independent of its kinase activity.
  • JM structure could serve as a biomarker for kinase-independent functions, guiding the development of novel allosteric inhibitors.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
21.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.4K